Blog

Projected revenues of $1.7 million for 2026 based on bGen ZERO execution milestones for Tempo project

Systems Purchase Agreement signed with Baran Energy for Tempo and Wolfson projects; Brenmiller to receive milestone-based payments, profits sharing, and service revenues

Brenmiller has 103 MWh in cumulative projects deployed, with numerous projects in development and a robust $500 million global pipeline of commercial opportunities

Signed private placement agreement for up to $25 million in equity financing to fund growth

ROSH HA‘AYIN, IL / ACCESS Newswire / September 30, 2025 / Brenmiller Energy Ltd. (NASDAQ:BNRG), (the “Company”, “Brenmiller” or “Brenmiller Energy”) a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, today reported financial results as of and for the six months ended June 30, 2025, in addition to operational and recent business development updates.

“We believe Brenmiller Energy has achieved more commercial and developmental milestones in 2025 to date than at any other time in our Company’s history,” stated Avi Brenmiller, Chairman and Chief Executive Officer of Brenmiller Energy. “Now, with our collaboration with Baran Energy in Israel, an agreement for up to $25 million in funding from one of our largest institutional shareholders, and continued momentum in Europe supported by non-dilutive project funding from the European Union, we believe Brenmiller is well funded for commercial ramp up.”

Significant Milestones Achieved, Supporting Upcoming Catalysts

• bGen ZERO won Gold Award at 2025 Edison Awards: bGen received the Gold Award in the Energy Storage and Management category at The Edison Awards, among the most prestigious accolades honoring excellence in new product and service development, marketing, design and innovation.

Summary of Financial Results

Income Statement:
Revenues were $387,000 for the six months ended June 30, 2025, compared to $0 in the same period of 2024. The revenues were generated from Brenmiller’s bGen installation with Enel, Italy’s largest utility. Operating loss was $6.57 million for the six months ended June 30, 2025, compared to $5.38 million in the same period of 2024. The increase was primarily due to the increased cost of revenues related to the finalization of the Enel project, a write-down of work-in-progress inventory to net realizable value, and higher operating costs not attributed to projects. These factors were partially offset by lower general and administrative expenses. Net loss was $7.45 million, compared to $1.58 million in the same period in 2024.

Balance Sheet:
As of June 30, 2025, Brenmiller had cash, cash equivalents, and restricted deposits totaling $2.16 million, compared to $4.13 million as of December 31, 2024. Subsequent to June 30, 2025, the Company has raised $5.2 million through equity offerings to one of its largest institutional shareholders.

Cash Flow Statement:
Net cash used in operating activities for the six months ended June 30, 2025 was $5.27 million, which was driven primarily by a net loss of $7.45 million and net cash provided by financing activities of $3.35 million.

About bGen™
bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.

About Brenmiller Energy Ltd.
Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing: the Company’s expectations for $1.7 million in revenues from the Tempo project during 2026; the Company’s 103 MWh in cumulative projects deployed, with numerous projects in development and a $500 million global pipeline of commercial opportunities; the Company’s expectation that Tempo will enter commercial operation and revenue generation in 2026 and Wolfson to ramp up for revenues by the end of 2026 or early 2027; that the installation of bGen at Tempo is estimated to save $7.5 million over 15 years and that the installation of bGen at Wolfson is estimated to save up to $1.3 million annually; that the Company may raise up to an additional $20 million in subsequent financing and that if all warrants are exercised, the overall financing may reach $50 million; that the SolWinHy Project in Spain is slated to commence in 2026 and that the Company expects to receive a purchase order for the bGen and associated services; that 5 MWe bGen is expected to contribute to the avoidance of 1.45 million tons of CO2 equivalent over 10 years and 5 MWe bGen is expected to achieve a 104% increase in energy efficiency; the Company’s anticipates further momentum in Europe; and that the Company believes its projects in Europe, including JV projects in development and in its pipeline, may qualify to apply for funding through the European Union Innovation Fund, as part of a €1 billion auction expected to open in December 2025. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

SOUTHLAKE, TX / ACCESS Newswire / September 30, 2025 / Allied OMS, the nation’s leading doctor-owned and doctor-led management services organization (MSO) for oral and maxillofacial surgeons, today announced the appointment of Bill Murray as Chief Financial Officer.

Bill brings more than two decades of experience guiding healthcare and technology companies through periods of rapid growth and transformation. He has led private equity-backed organizations, raised significant capital to fund expansion, and built scalable financial and operational systems. His background in healthcare services, analytics, and technology positions him to help Allied strengthen its platform and accelerate its next phase of growth.

According to Dan Hosler, CEO of Allied OMS, Bill’s experience aligns perfectly with the company’s trajectory: “Bill’s record of building and scaling high-growth healthcare businesses is what we need as Allied OMS accelerates its expansion nationwide. His ability to align financial strategy with operational execution will help us deliver on our mission of creating the doctor-led partnership for the future of oral surgery.”

Bill noted that Allied OMS’s distinctive structure was a key factor in his decision to join: “I was drawn to Allied OMS because of its unique doctor-led model and its focus on alignment around patient outcomes. Too often, financial targets and clinical priorities can work against each other – here, they move in lockstep. I’m excited to help drive growth while ensuring our surgeons have the support, resources, and autonomy they need to thrive.”

Dr. Jonathon Jundt, Co-Founder and Chief Medical Officer at Allied OMS, added: “Growth only matters if it translates into real benefits for surgeons and patients. Bill’s leadership will ensure we continue investing in the resources, support, and infrastructure that allow our doctors to practice the way they want while expanding access to care.”

Bill’s appointment follows Allied OMS’s recent minority investment from 65 Equity Partners, which provides additional capital to accelerate the platform’s growth. With Bill’s financial leadership, Allied is poised to advance its strategy – partnering with like-minded oral and maxillofacial surgeons who want to shape the future of the specialty, recruiting residents and associates into careers they love, opening de novo locations to expand patient care, and helping existing practices maximize their growth potential. His expertise will ensure these initiatives are executed sustainably while strengthening the only doctor-led oral surgery platform in the country.

About Allied OMS

Allied OMS is a doctor-owned, doctor-led, and doctor-governed MSO that partners with oral and maxillofacial surgery practices across the U.S. Combining the autonomy of private practice with the scale and sophistication of institutional support, Allied OMS empowers surgeons to lead the future of their specialty. The company currently supports surgeons in 50+ locations and maintains doctor leadership across all major committees and its Board of Directors. Learn more at www.alliedoms.com.

###

Sara Tumen Weinberg
Chief Marketing Officer
Allied OMS
sweinberg@alliedoms.com

SOURCE: Allied OMS

View the original press release on ACCESS Newswire

With major product development milestones achieved, CyberSentriq expands its portfolio with flexible custom bundles, strengthening its leadership in cybersecurity and data protection solutions.

LONDON, GB / ACCESS Newswire / October 1, 2025 / CyberSentriq, an integrated cybersecurity and data protection platform, today announces new Product updates across its comprehensive cybersecurity and data protection portfolio. Each of these solution updates gives security professionals more powerful tools to protect people and assets while streamlining operations. CyberSentriq was formed through the acquisition of TitanHQ and its merger with Redstor, a Bregal Milestone portfolio company.

The releases demonstrate CyberSentriq’s commitment to providing integrated cybersecurity and data protection solutions that address the full spectrum of modern security challenges.

Recent Product Development Milestones:

The latest updates from CyberSentriq focus on delivering more reliable performance and an intuitive user experience for security teams. Key enhancements include:

Product Highlights: Cybersecurity & Data Protection

● Social Engineering detection and protection

More powerful and advanced social engineering detection, powered by Natural Language Processing (NLP) added to phishing protection. Our NLP is interpreting email intentions and blocking new, sophisticated phishing attacks.

● Improved detection accuracy through real-time reporting and feedback

We’ve enhanced how users can report phishing attacks and simulations, which continuously improves our detection accuracy. All customers benefit from all enhanced reporting. This addition trains and improves our AI and ML detection models.

● Vast improvements in our administrator functionality

We’ve listened to our admin community and added features, including enhanced end-user configurations, bulk upload for allow/block lists, DMARC bypassing, enhanced remediation control, and roles & permissions.

● MSP improvements

Easier MSP platform branding and the very popular Monitor Mode, where you can monitor the effectiveness of email security without disrupting end users.

James Griffin, CEO at CyberSentriq, commented on the latest developments, “Our latest product enhancements show how seriously we take customer feedback, and by improving detection, recovery, and administration, we’re giving security teams more control, better accuracy, and greater resilience to stay ahead of today’s rapidly evolving cyber threats.”

● Recover to a Different Account for Microsoft 365 & Google Workplace – Users can recover Exchange, OneDrive, Gmail, or GDrive accounts to different accounts – great for when an admin needs to recover ex-employee data to their line manager.

● Entra ID Backup Enhancements – Now market-leading, covering users, groups, admin units, roles, and enterprise apps. Includes relationship recoveries, bulk recoveries, and filtering options.

● Microsoft 365 Backup Alternate Restore – Admins can now restore Exchange, OneDrive, Gmail, or Google Drive data into a different mailbox or account.

● Azure VM Backup Policies – New VM policies with support for multiple daily snapshots, giving admins more control and recovery points.

● Selection of RedApp feature and functionality improvements – including the much-requested ConnectWise PSA Integration, allowing you to sync tickets and updates automatically.

CyberSentriq Innovation Roadmap

Looking ahead, we’re working on several developments designed to take the CyberSentriq cybersecurity and data protection platform to the next level. Highlights include

● MX Integration – A unified experience that combines Secure Email Gateway and ICES, with MX record-based routing plus pre-inbox threat detection backed by advanced API-level protection.

● Next-Generation Security Awareness Training – AI-driven lure generation and enhanced training content for even greater end-user resilience.

● Platform Integration – Planned for Q4, users will be able to switch seamlessly between the data protection platform, email security platform, and partner portal.

“Email is where business happens, and it’s also where risk lives..By combining email archiving, backup, recovery, and cybersecurity, we’re delivering resilience, compliance, and operational efficiency in one solution. This is exactly what our SMBs and MSPs customers have told us they need in today’s environment,” added Griffin.

CyberSentriq also announces the general availability of its new cybersecurity and data protection bundle, bringing together essential security services in a single, streamlined solution designed to protect, retain, and recover business-critical communications.

With the rise of compliance requirements, cyber threats, and accidental data loss, SMBs and Managed Service Providers (MSPs) are seeking more innovative ways to safeguard email, the backbone of business communication. The CyberSentriq bundles are designed for organisations that need to meet security and compliance standards without relying on fragmented tools.

This quarter, we launched CyberSentriq Bundles, bringing the best of our cybersecurity and backup solutions into a simple, powerful package.

What’s Included

● Multi-layer Email Protection (MX & ICES)

● Microsoft 365 Backup and Recovery

● AI-Driven Phishing Defense

● Security Awareness Training & Phishing Simulation

These bundles are cloud-native, MSP-friendly, and scalable, making them ideal for IT teams and growing businesses that require robust security without complexity.

“With these new bundles we’re making enterprise-grade security accessible, flexible, and easy to deploy, giving SMBs and MSPs the confidence to protect their business without adding complexity,” concluded Griffin.

The new custom bundles are now available immediately through CyberSentriq and its extensive partner network. For more information about CyberSentriq’s Bundles, visit

https://www.cybersentriq.com/bundles

About CyberSentriq
CyberSentriq is an integrated cybersecurity and data protection platform that leverages solutions from two best-of-breed vendors in the MSP space. Partnering with over 3,000 MSPs and protecting over 150,000 SMBs globally, CyberSentriq provides an unmatched combination of proactive AI-driven email and web security, advanced data protection, and operational resilience.

The CyberSentriq platform offers:

● AI-driven threat intelligence and detection

● Advanced email security at both the Mail Exchange (MX) and Integrated Cloud Email Security (ICES) layers.

● Cloud-based data backup and recovery

● Security awareness services

● Email archiving and encryption.

For more information, visit www.CyberSentriq.com

SOURCE: CyberSentriq

Related Images

View the original press release on ACCESS Newswire

WASHINGTON, D.C. / ACCESS Newswire / September 30, 2025 / AGS Health, a leading provider of tech-enabled revenue cycle management (RCM) solutions and a strategic growth partner to healthcare providers across the U.S., has been named a recipient of the UiPath AI25 Award for its pioneering use of agentic AI automation to assist healthcare providers in managing the rising rate of costly healthcare claim denials.

Through their Denial Management Agents, AGS Health helps healthcare providers to reduce preventable denials, expedite appeals, and improve clean claim rates, projecting gains of up to 6 percent in clean claims and 20-26 percent faster handling times. This achievement, which marks the company’s second consecutive UiPath AI25 Award following recognition in 2024, reflects its innovative hybrid workforce model where UiPath bots, AI agents, and skilled human specialists work seamlessly across critical RCM workflows such as prior authorization validation, denial classification and follow-up, medical necessity rejections, and timely filing checks. In this model, AI agents handle analysis and reasoning, bots manage routine tasks, and human experts oversee high-risk cases, audit, and quality control, ensuring efficiency and accuracy.

“These winners are breaking new ground with agentic automation. They’re orchestrating people, AI, and robots to transform processes and deliver measurable impact,” said Graham Sheldon, Chief Product Officer at UiPath and Executive Sponsor for the AI25 Awards. “We’re proud to recognize their achievements and excited to see how they continue pushing the boundaries of what’s possible.”

The UiPath AI25 Awards spotlight the 25 most innovative implementations of the UiPath Platform^™ for agentic automation. Winners demonstrate measurable ROI, productivity gains, and transformative business impact by orchestrating agents, bots, and people. Recognition spans both proven outcomes and promising early-stage initiatives that showcase the future of automation.

“AGS Health has embraced the healthcare industry’s shift toward autonomous operations while keeping human expertise at the center,” says Patrice Wolfe, CEO of AGS Health. “Our hybrid intelligence approach merges the speed and scalability of AI agents with the judgment and empathy of skilled professionals. This recognition by UiPath reaffirms our focus on building smarter, faster, and more autonomous processes that increase accuracy, efficiency, and financial performance with expert human oversight.

Adds AGS Health CIO Thomas Thatapudi, “Agentic automation enables us to deliver faster, more accurate RCM services, which is crucial for healthcare providers navigating cost pressures and rising claim volumes. By automating high-volume, error-prone tasks, we’re helping reduce denials and improve first-pass rates, directly enhancing our customers’ cash flow.”

About AGS Health

AGS Health is more than a revenue cycle management company-we’re a strategic partner for growth. Our distinctive methodology blends award-winning services with intelligent automation and high-touch customer support to deliver peak end-to-end revenue cycle performance and an empowering patient financial experience.

We employ a team of 15,000 highly trained and college-educated RCM experts who directly support customers spanning a variety of care settings and specialties, including nearly half of the 20 most prominent U.S. hospitals and 40% of the nation’s 10 largest health systems. Our thoughtfully crafted RCM solutions deliver measurable revenue growth and retention, enabling customers to achieve the revenue to realize their vision.

# # #

Media Contact:

Liz Goar, NPC Creative Services
liz@npccs.com

SOURCE: AGS Health

View the original press release on ACCESS Newswire

LACONIA, NEW HAMPSHIRE / ACCESS Newswire / September 30, 2025 / ePropelled, a leading innovator in high-efficiency electric propulsion for unmanned vehicles, has reached a major milestone with 47 granted and pending patents across 13 product families. The company’s expanding IP portfolio reflects breakthrough technologies for electric mobility across air, land, sea, and industrial sectors.

“This achievement shows how quickly our team is turning ideas into real-world solutions,” said Nick Grewal, ePropelled Founder, Chairman & CEO. “We’re focused on creating cleaner, lighter, and more affordable electric propulsion for unmanned vehicles, in the air, on the ground and in the sea, while protecting the innovations that make it possible.”

Recent milestones include:

• US12323039B2: A newly granted US patent for an advanced uncrewed aerial vehicle (UAV) generator design (June 2025)

• EP3973620A1: This European patent application relates to an advanced cooling of a UAV generator, which is scheduled to be granted in October 2025

• Design patents: Covering electric machines with integrated cooling and drive circuits

ePropelled continues to develop and protect multiple core concepts behind its dynamic torque switching (eDTS™) technology and hybrid electric-jet systems, aimed at next-generation aircraft and electric vertical take-off and landing aircraft (eVTOL).

“Every patent begins with solving a real customer problem,” said Dr. Nabeel Shirazee, ePropelled Global CTO. “Our engineers focus on ideas that lower energy use, increase range, or streamline manufacturing for our partners.”

ePropelled’s growing patent portfolio underscores its leadership in powering the future of electrification.

SOURCE: ePropelled, Inc.

View the original press release on ACCESS Newswire

Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments

SEATTLE, WASHINGTON / ACCESS Newswire / October 1, 2025 / The Cancer AI Alliance (CAIA) – a research collaboration of top cancer centers – today announced the first scalable platform using federated learning for cancer research.

CAIA is comprised of National Cancer Institute-designated cancer centers Dana-Farber Cancer Institute, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, and The Sidney Kimmel Comprehensive Cancer Center and Whiting School of Engineering at Johns Hopkins with financial and technical support from technology industry leaders Amazon Web Services (AWS), Deloitte, Ai2 (Allen Institute for AI), Google, Microsoft, NVIDIA and Slalom.

The platform serves as the technological foundation of CAIA’s aim to save more lives by enabling researchers and clinicians to train AI models that learn from participating cancer centers’ millions of clinical data points while maintaining data security, privacy and adherence to regulatory and ethical standards.

“We are at an urgent inflection point in both cancer research and AI, and this platform enables us to rise to this moment by rapidly advancing cancer research, treatments and care,” said Jeff Leek, PhD, vice president and chief data officer at Fred Hutch and holder of the J. Orin Edson Foundation Endowed Chair.

“Currently, it takes years to uncover new insights that can be translated into better treatments and care, but this platform will accelerate the pace of breakthrough discoveries by up to tenfold, reducing that time from years to months,” said Leek, who is also the founder and scientific director of CAIA and a member of its steering committee.

“It cannot be overstated how momentous it is that we came together to launch this platform in just one year, and we did it as a unified alliance with a shared mission to eradicate cancer,” said Brian M. Bot, director of the strategic coordinating center for CAIA.

While federated learning – a machine learning method that preserves anonymity of individual data – has been gaining steam for nearly 10 years, adapting the technology for multi-institution use in cancer research has proved elusive due to significant technological, regulatory, patient privacy and data harmonization challenges, as well as the coordination effort necessary to bring together organizations of this scale and complexity.

Development of CAIA’s platform was possible due to an intense focus on collaboration and a drive for collective action across the participating cancer centers and technology companies, resulting in a unified technical, legal and governance structure.

“CAIA represents a strategic shift leveraging collective strength rather than isolation,” said Anaeze Offodile, MD, MPH, chief strategy officer of Memorial Sloan Kettering Cancer Center. “By combining MSK’s clinical expertise with the alliance’s capital, network of technology partners, data and federated framework, we can accelerate meaningful advances in cancer care while upholding the highest standards of security and integrity. Together, we move closer to the shared goal of reducing-and ultimately eliminating-the burden of cancer.”

The federated learning platform works like this: participating cancer centers implement federated learning technology at their institutions, each connecting to a centralized orchestration component of the platform. Using this architecture, AI models travel to each participating cancer center’s secure data to learn from it locally, generating a summary of its learnings without individual clinical data ever leaving institutional firewalls. The insights gained from training the model on each cancer center’s de-identified data are then aggregated centrally to strengthen the AI models to uncover patterns, maximizing the value of the collective knowledge base.

Enabling researchers to develop models on data from multiple cancer centers through a collaborative, federated learning ecosystem creates a paradigm shift from solving problems in isolation to solving them together. More importantly, these updated AI models could significantly improve health outcomes for cancer patients by revealing trends across more diverse populations and rare cancers.

“CAIA will enable unprecedented exploration of AI models for cancer patient data, through a privacy-aware technical framework and a collaborative research alliance,” said Alexis Battle, PhD, professor of biomedical engineering and computer science, and director of the Malone Center for Engineering in Healthcare, and director for Research Strategy and Partnerships, Data Science and AI Institute at the Johns Hopkins Whiting School of Engineering.

“This could serve as a model for every cancer center in the country to join CAIA in this collaborative effort to unlock innovation in cancer care,” continued Vasan Yegnasubramanian, MD, PhD, professor of oncology, pathology, and radiation oncology and molecular radiation sciences at the Johns Hopkins Kimmel Cancer Center and director of inHealth Precision Medicine at Johns Hopkins Medicine. Battle and Yegnasubramanian are members of the steering committee for CAIA.

Eight unique projects are being launched by researchers across the participating cancer centers. These initial projects aim to tackle some of oncology’s most persistent challenges, from predicting treatment response to identifying novel biomarkers and analyzing rare cancer trends. The projects use the federated learning platform and structured, de-identified data housed securely by participating cancer centers, which collectively provides a diverse and representative foundation of over 1 million patients for modeling and analysis.

The platform’s true power, however, lies in its potential to scale up. Over the next year, CAIA plans to enable dozens of research models and add more participants to the alliance.

“With the launch of CAIA we have laid a critical foundation in the effort to accelerate new discoveries and the combined data from our cancer centers can now power these innovative AI models. We are excited to share these models with research centers across the nation and exponentially expand access to the data that will drive progress toward better diagnosis, treatment and outcomes for cancer patients everywhere,” said Eliezer Van Allen, MD, Chandra Nohria Family Chair for AI in Cancer Research at Dana-Farber Cancer Institute.

# # #

Additional CAIA collaborator quotes

“AWS is immensely proud to help power this industry-first collaboration with our cloud technology and LLM platforms, in support of CAIA’s mission to transform cancer research and care,” said Dr. Angela Shippy, Senior Physician Executive and Clinical Innovation Lead at Amazon Web Services. “Collaboration often leads to discovery, and I’m eager to see what medical breakthroughs come from the collective expertise of these world-class cancer centers and global technology leaders.”

“At Deloitte, we believe collaboration drives progress,” said Jason Girzadas, CEO of Deloitte US. “CAIA brings together leaders across industries to address one of the world’s most critical health challenges. The unprecedented speed of developing and delivering CAIA’s platform is made possible through each individual group driving toward this common goal, and Deloitte is proud to bring AI and strategy expertise to the Alliance.”

“We are proud to be part of this effort to bring the power of AI to the complex problem of cancer research,” said Ali Farhadi, CEO of Ai2. “CAIA’s ability to bring together cancer centers in a collaborative effort with our state of the art AI tools is a powerful combination that will accelerate scientific progress and save lives. It’s been incredible to see our tools in the hands of oncologists and researchers, where their early efforts have already demonstrated incredible potential to unlock discoveries that could reshape healthcare and deliver life-changing outcomes for patients.”

“Google is honored to continue to partner with the Cancer AI Alliance,” said Reymund Dumlao, Director, State and Local Government and Education, Google Public Sector. “This groundbreaking initiative represents a pivotal moment in our collective pursuit to eradicate cancer. By integrating advanced federated AI technologies with the expertise and data resources of leading cancer centers, we are establishing a secure, scalable platform designed to accelerate scientific discovery. This collaborative ecosystem will enable a unified effort against cancer, transforming research methods and expediting the delivery of innovative treatments to patients globally.”

“The collaborative work that CAIA has done will revolutionize how medical research is done, accelerate scientific discovery, and save lives,” said Dr. William Weeks, Director of Health, Microsoft AI for Good Lab.

“At Slalom, we see the future of health as being the convergence of technology, data, and strategy to build better tomorrows for all,” said Brenda Young, managing director at Slalom. “CAIA demonstrates how collaboration between leading cancer centers and technology partners can unlock new insights and reshape the use of Data & AI to diagnose, treat, and prevent cancer. We look forward to our continued partnership as we pave the way for transformative breakthroughs in health.”

Media Contact:
Molly McElroy and Christina VerHeul
media@fredhutch.org
206-667-2210

About the Cancer AI Alliance (CAIA)

The Cancer AI Alliance (CAIA) is comprised of the nation’s top cancer centers with support from technology industry leaders. CAIA aims to accelerate cancer discovery and treatment. Since its founding in 2024, CAIA has secured $65M in financial and technical support. Through this unprecedented collaboration, CAIA launched the first scalable, multi-cloud federated learning platform for cancer research, which enables researchers to train AI models on diverse, multi-institutional clinical data while maintaining data security and privacy. By combining the collective knowledge of its members, CAIA is on a mission to redefine the cancer research landscape.

Dana-Farber Cancer Institute  

Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. Dana-Farber’s mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement and advocacy. Dana-Farber is a federally designated Comprehensive Cancer Center and a teaching affiliate of Harvard Medical School.

Dana-Farber is the only hospital nationwide with a top 3 U.S. News & World Report Best Cancer Hospital ranking in both adult and pediatric care.

As a global leader in oncology, Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world, offering more than 1,100 clinical trials. 

Fred Hutch Cancer Center

Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.

Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program. 

Johns Hopkins University

As the nation’s first research university, Johns Hopkins’ mission is to foster cutting-edge research and innovation, to educate its students and cultivate their capacity for lifelong learning, and to bring thebenefits of discovery to the world through its 10 world-renowned schools, and numerous institutes and centers.

Sidney Kimmel Comprehensive Cancer Center
Since our founding more than 50 years ago, our medical pioneers led the way to understanding cancer through impactful research, developing novel therapies, and attending to the complex needs of patients. Our experts mapped the genomic blueprints for cancer, deciphered the epigenome, discovered ways to make the immune system fight cancer, eliminated the need for perfect matches in bone marrow transplant, pioneered life-saving surgeries, and brought proton therapy and other advanced technologies in radiation therapy.

Whiting School of Engineering
We advance data- and science-driven engineering discovery, innovation, and systems applications to help everyone live longer and healthier lives and empower communities and society to thrive even in extreme environments. With more than 26 research centers and institutes – including the Data Science and AI Institute – and through strong community, university, and industry partnerships, Hopkins Engineering is a driving force in the future of technology, health care, and engineering education.

Memorial Sloan Kettering Cancer Center

The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world’s most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years. www.mskcc.org

Contact Information

Christina VerHeul
Associate Vice President, Communications
media@fredhutch.org
(206) 667-2210

Molly McElroy
Sr. Communications Manager
mwmcelro@fredhutch.org
206-667-2210

SOURCE: Fred Hutch Cancer Center

View the original press release on ACCESS Newswire